HC Wainwright Predicts Cingulate FY2025 Earnings

Cingulate Inc. (NASDAQ:CING) – HC Wainwright issued their FY2025 earnings estimates for Cingulate in a report issued on Thursday, January 30th. HC Wainwright analyst R. Selvaraju forecasts that the company will earn ($2.97) per share for the year. HC Wainwright currently has a “Buy” rating and a $20.00 target price on the stock. The consensus estimate for Cingulate’s current full-year earnings is ($11.69) per share.

Cingulate (NASDAQ:CING) last issued its quarterly earnings results on Thursday, November 7th. The company reported ($1.83) EPS for the quarter, beating the consensus estimate of ($2.22) by $0.39.

CING has been the topic of a number of other research reports. Roth Mkm assumed coverage on Cingulate in a research report on Friday, January 10th. They issued a “buy” rating and a $12.00 price target on the stock. Roth Capital raised shares of Cingulate to a “strong-buy” rating in a report on Friday, January 10th. Finally, Maxim Group upgraded shares of Cingulate from a “hold” rating to a “buy” rating in a report on Wednesday, November 20th.

Cingulate Stock Performance

Shares of NASDAQ CING opened at $4.55 on Friday. The business’s fifty day simple moving average is $4.59 and its 200-day simple moving average is $4.53. Cingulate has a 12-month low of $1.80 and a 12-month high of $58.32.

Institutional Trading of Cingulate

A hedge fund recently raised its stake in Cingulate stock. AlphaMark Advisors LLC grew its holdings in Cingulate Inc. (NASDAQ:CING) by 50,000.0% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 5,010 shares of the company’s stock after acquiring an additional 5,000 shares during the quarter. AlphaMark Advisors LLC owned about 0.16% of Cingulate worth $25,000 at the end of the most recent reporting period. 41.31% of the stock is owned by institutional investors and hedge funds.

About Cingulate

Cingulate Inc, a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company’s stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults.